Zobrazeno 1 - 10
of 761
pro vyhledávání: '"Gary R. Lichtenstein"'
Autor:
David T. Rubin, Walter Reinisch, Thomas Greuter, Paulo G. Kotze, Marcia Pinheiro, Rajiv Mundayat, Eric Maller, Marc Fellmann, Nervin Lawendy, Irene Modesto, Stephan R. Vavricka, Gary R. Lichtenstein
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 14 (2021)
Introduction: Extraintestinal manifestations (EIMs) in patients with ulcerative colitis (UC) are common. Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of UC. We evaluated the efficacy of tofacitinib in patients with
Externí odkaz:
https://doaj.org/article/e097ca53b86849d19e2e7355909c6a94
Autor:
Gary R. Lichtenstein, MD, Michael F. Picco, MD, PhD, Sanjeev Solomon, MD, Stephen J. Bickston, MD
Publikováno v:
VideoGIE, Vol 3, Iss 2, Pp 35-42 (2018)
Externí odkaz:
https://doaj.org/article/7cb5beb18cfd49cc9b26a0b3deb7a990
Publikováno v:
Clinical Medicine Insights: Gastroenterology, Vol 2012, Iss 5, Pp 11-21 (2012)
Externí odkaz:
https://doaj.org/article/6dc149e403f8496599e222b84a8d4d25
Publikováno v:
Clinical Medicine Insights: Gastroenterology, Vol 4 (2011)
Mesalamine (5-ASA) has been the mainstay therapy of mild to moderate active ulcerative colitis both as an induction and maintenance treatment. Multimatrix system (MMX) 5-ASA is a recently developed formulation of 5-ASA allowing for slow and gradual r
Externí odkaz:
https://doaj.org/article/99e2de270fc14f9fa39a4e65a8c65335
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 1 (2008)
Adalimumab (ADA) is a subcutaneously (SC) self-administered fully human Ig G1 monoclonal antibody directed against tumor necrosis factor alpha (TNFα). In the CLASSIC I dose-ranging trial, ADA was superior to placebo for inducing remission in patient
Externí odkaz:
https://doaj.org/article/d5b4c14bce75435b8e06604439c3eb41
Autor:
Gary R. Lichtenstein, Benjamin L. Cohen, Leonardo Salese, Irene Modesto, Wenjin Wang, Gary Chan, Haytham Mohamed Ahmed, Chinyu Su, Laurent Peyrin-Biroulet
Publikováno v:
Digestive Diseases and Sciences. 68:2624-2634
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ae82b32df57d3c3d63e043cc22e897f1
https://doi.org/10.1007/s10620-022-07794-0
https://doi.org/10.1007/s10620-022-07794-0
Autor:
Sophie Shubow, Qin Sun, Ai Len Nguyen Phan, Dana C. Hammell, Maureen Kane, Gary H. Lyman, Allan Gibofsky, Gary R. Lichtenstein, Zachary Bloomgarden, Raymond K. Cross, Sarah Yim, James E. Polli, Yow‐Ming Wang
Publikováno v:
Clinical Pharmacology & Therapeutics. 113:37-49
The approval and adoption of biosimilar products are essential to contain increasing healthcare costs and provide more affordable choices for patients. Despite steady progress in the number of the US Food and Drug Administration (FDA) biosimilar appr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5dc4e8a450b0e5f29824c29bffbe05d9
https://doi.org/10.1002/cpt.2765
https://doi.org/10.1002/cpt.2765
Autor:
Shivali Berera, Gary R. Lichtenstein
Publikováno v:
Current Treatment Options in Gastroenterology. 20:81-100
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::77bcc8bcec4243366cacc149c7b2c0a8
https://doi.org/10.1007/s11938-022-00371-4
https://doi.org/10.1007/s11938-022-00371-4
Publikováno v:
Pediatric Inflammatory Bowel Disease ISBN: 9783031147432
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f02eb97b8a28693f21fcd8b3d5db1c33
https://doi.org/10.1007/978-3-031-14744-9_35
https://doi.org/10.1007/978-3-031-14744-9_35
Autor:
Gary R Lichtenstein, Brian Bressler, Carlos Francisconi, Severine Vermeire, Nervin Lawendy, Leonardo Salese, Gosford Sawyerr, Hongjiong Shi, Chinyu Su, Donna T Judd, Thomas Jones, Edward V Loftus
Background In patients with ulcerative colitis (UC), risks of infection and malignancies increase with age. Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of UC. This analysis assessed age as a risk factor for adverse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94700e81811a66a2373881de060c9ccb
https://lirias.kuleuven.be/handle/20.500.12942/707119
https://lirias.kuleuven.be/handle/20.500.12942/707119